You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: February 28, 2024

Pazopanib hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for pazopanib hydrochloride and what is the scope of patent protection?

Pazopanib hydrochloride is the generic ingredient in two branded drugs marketed by Apotex, Sun Pharm, Teva Pharms Inc, and Novartis, and is included in four NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Pazopanib hydrochloride has forty patent family members in twenty-five countries.

There are four drug master file entries for pazopanib hydrochloride. Five suppliers are listed for this compound.

Summary for pazopanib hydrochloride
International Patents:40
US Patents:1
Tradenames:2
Applicants:4
NDAs:4
Drug Master File Entries: 4
Finished Product Suppliers / Packagers: 5
Raw Ingredient (Bulk) Api Vendors: 102
Clinical Trials: 284
Patent Applications: 1,401
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in pazopanib hydrochloride?pazopanib hydrochloride excipients list
DailyMed Link:pazopanib hydrochloride at DailyMed
Recent Clinical Trials for pazopanib hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alliance for Clinical Trials in OncologyPhase 2/Phase 3
Shenzhen Chipscreen Biosciences Co.LtdPhase 2
University Hospital, BordeauxPhase 1/Phase 2

See all pazopanib hydrochloride clinical trials

US Patents and Regulatory Information for pazopanib hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 215837-001 Oct 19, 2023 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Apotex PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 217713-001 Oct 19, 2023 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Teva Pharms Inc PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 217517-001 Oct 19, 2023 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for pazopanib hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for pazopanib hydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1343782 SPC/GB10/032 United Kingdom ⤷  Try a Trial PRODUCT NAME: PAZOPANIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU 1/10/628/001 20100614; UK EU 1/10/628/002 20100614; UK EU 1/10/628/003 20100614; UK EU 1/10/628/004 20100614
1343782 CA 2010 00024 Denmark ⤷  Try a Trial PRODUCT NAME: PAZOPANIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER HYDROCLORID
1343782 122010000038 Germany ⤷  Try a Trial PRODUCT NAME: PAZOPANIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614
1343782 2010C/030 Belgium ⤷  Try a Trial PRODUCT NAME: PAZOPANIB, OPTIONNELLEMENT SOUS LA FORME DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE OU DE SON SOLVATE; AUTHORISATION NUMBER AND DATE: EU/1/110/628/01 20100616
1343782 389 Finland ⤷  Try a Trial
1343782 C01343782/01 Switzerland ⤷  Try a Trial FORMER OWNER: GLAXOSMITHKLINE LLC, US
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.